Treatment resistance and metastasis depend on cellular plasticity. In this process the cancer cells switch from a non-motile and well-differentiated phenotype to a migratory and de-differentiated phenotype. We are investigating the intrinsic and extrinsic factors/mechanisms involved in such cellular plasticity aiming to identify molecular nodes that can be utilized as targets for anti-cancer treatment. The project group headed by Prof Kristin Austlid Taskén is studying neuronal differentiation of prostate cancer, while the Lina Prasmickaite project group is focusing on phenotype switching in breast cancer and melanomas.
Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma
Br J Cancer (in press)
Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study
Acta Oncol, 61 (8), 955-962
Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192]
J Control Release, 349, 1